A practical reference on drug affinity complex: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
=== "Hakbang ng Maisug" rallies === Additional nationwide protests, called Hakbang ng Maisug (brave) prayer rallies, were held in Dumaguete, Tagum, and Angeles by Duterte and Quiboloy's supporters, who voiced their grievances against the Marcos administration. Particularly among these grievances included their opposition to proposed constitutional amendments and to the increased US military presence in the country, as well as denouncement of perceived censorship under the administration. In one of the rallies, Duterte notably accused Marcos of plotting to extend his term beyond the current term limit of the Constitution and of being a drug addict, to which Marcos responded by alleging Duterte's previous use of fentanyl as painkiller impaired his judgment; Duterte later dared Marcos to undergo a drug test with him at Luneta Park. Frustrated on the administration's use of taxpayers' money, Duterte initially revived calls advocated by former House Speaker Pantaleon Alvarez for Mindanao to secede from the Philippines; his calls drew disapproval from several lawmakers and former Muslim rebels, prompting Duterte to later retract his calls, saying he only wanted "a better deal for Mindanao". Despite success in holding some rallies, a few suffered setbacks and cancellations after the rally venues were allegedly blocked by the Marcos administration, drawing condemnation from Duterte and his allies.
=== Plagiarism === In June 2011, bloggers at Deterritorial Support Group, as well as Yahoo! Ireland editor Brian Whelan, discovered that Hari had plagiarised material published in other interviews and writings by his interview subjects. For example, a 2009 interview with Afghan women's rights activist Malalai Joya included quotations from her book Raising My Voice in a manner that made them appear as if spoken directly to Hari. A piece entitled "How Multiculturalism Is Betraying Women" which Hari submitted when entering the Orwell Prize was plagiarised from Der Spiegel. Hari initially denied any wrongdoing, stating that the unattributed quotes were for clarification and did not present someone else's thoughts as his own. However, he later said that his behaviour was "completely wrong" and that "when I interviewed people, I often presented things that had been said to other journalists or had been written in books as if they had been said to me, which was not truthful." Hari was suspended for two months from The Independent and in January 2012 it was announced that he was leaving the newspaper. The Media Standards Trust instructed the council of the Orwell Prize, who had given their 2008 prize to Hari, to examine the allegations. The council concluded that "the article contained inaccuracies and conflated different parts of someone else's story" and did not meet the standards of Orwell Prize-winning journalism. Hari returned the prize, though he did not return the prize money of £2,000.
=== Generic names === Progesterone is the generic name of the drug in English and its INNTooltip INN, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCITTooltip Denominazione Comune Italiana, and JANTooltip Japanese Accepted Name, while progestérone is its name in French and its DCFTooltip Dénomination Commune Française. It is also referred to as progesteronum in Latin, progesterona in Spanish and Portuguese, and progesteron in German.
== Sources == Bushkovitch, Paul (5 December 2011). A Concise History of Russia. Cambridge University Press. ISBN 978-1-139-50444-7. Crummey, Robert O. (6 June 2014). The Formation of Muscovy 1300 - 1613. Routledge. ISBN 978-1-317-87200-9. Fennell, John (15 November 2023). The Emergence of Moscow, 1304–1359. Univ of California Press. ISBN 978-0-520-34759-5. Kuchkin, Vladimir A. (2013). "Московское великое княжество" [Grand Principality of Moscow]. In Kravets, S. L. (ed.). Большая российская энциклопедия. Том 21: Монголы — Наноматериалы (in Russian). Большая российская энциклопедия. pp. 308–310. ISBN 978-5-85270-355-2. Archived from the original on 20 May 2026. Riasanovsky, Nicholas V.; Steinberg, Mark D. (2019). A history of Russia (Ninth ed.). New York: Oxford University Press. ISBN 978-0-19-064558-8. Smirnova, E. S. (2013). "Московская школа" [Moscow school]. In Kravets, S. L. (ed.). Большая Российская энциклопедия. Том 21: Монголы — Наноматериалы (in Russian). Большая Российская энциклопедия. pp. 273–274. ISBN 978-5-85270-355-2.
In a study looking at gene polymorphisms of GPX1 and other oxidative stress genes in relation to prevalence of Type 2 diabetes mellitus, Banerjee, et al., found that while no association was found in expression of most GPX1 polymorphisms and risk of Type 2 diabetes mellitus, having the C allele of GPX1 led to a 1.362 times higher risk of the disease, highlighting the importance of finding individuals in the population with this gene variant to help treat them early on. Recent work by Alan M. Diamond and colleagues has shown that allelic variations of GPX1, like the codon 198 polymorphism that results in leucine or proline and an increase in alanine repeat codons, can result in different localization levels in MCF-7 human breast carcinoma cells. For instance, the allele expressing the leucine-198 polymorphism and 7 alanine repeats generates GPX-1 localization that is disproportionately in the cytoplasm as compared to other allelic variants. To further understand the effects of these variants on GPX-1 function, mutant GPX-1 with mitochondrial localization sequences were generated and the GPX-1 infused cells were analyzed for their response to oxidative stress, energy metabolism and cancer-associated signaling molecules. Ultimately, GPX-1 variants heavily influenced cellular biology, suggesting that different GPX-1 variants affect cancer risk differently.
Sources: en.wikipedia.org
== Use == Areas of increased pigmentation such as moles may be depigmented to match the surrounding skin. Effective agents for specific areas include corticosteroids, tretinoin, and hydroquinone. These agents are not allowed in cosmetics in Europe due to concerns about side effects. Attempts to whiten large areas of skin may also be carried out by certain cultures. This may be done for reasons of appearance, politics, or economics. Skin whiteners can help achieve lighter skin tones, but many of them contain harmful ingredients, such as the steroid clobetasol propionate, inorganic mercury (mercuric chloride or amalgamated mercury), glutathione (an antioxidant traditionally used in cancer treatment), and the organic compound hydroquinone. Skin lighteners' main health risks are linked to (i) The overuse of topical clobetasol, which can cause systemic steroid effects from daily usage, especially on broad skin regions; and (ii) concealed mercury content, which can lead to mercury poisoning depending on individual susceptibility. Many skin whiteners contain a toxic form of mercury as the active ingredient. Their use, therefore, may harm a person's health and is illegal in many countries.
Subdermal hematoma (under the skin) Intramuscular hematoma (inside muscle tissue) Skull/brain: Subgaleal hematoma – between the galea aponeurosis and periosteum Cephalohematoma – between the periosteum and skull. Commonly caused by vacuum delivery and vertex delivery. Epidural hematoma – between the skull and dura mater Subdural hematoma – between the dura mater and arachnoid mater Subarachnoid hematoma – between the arachnoid mater and pia mater (the subarachnoid space) Othematoma – between the skin and the layers of cartilage of the ear Breast hematoma (breast) Perichondral hematoma (ear) Perianal hematoma (anus) Subungual hematoma (nail) Rectus sheath hematoma Genital hematoma
== Types == Types include those acting directly as membrane-bound receptors (Receptor protein serine/threonine kinase) and intracellular kinases participating in Signal transduction. Of the latter, types include:
=== Recent developments in non-invasive brain stimulation (TMS / tDCS) === During the past several years, both transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) have experienced significant evidence, regulatory analysis, and clinical implementation. According to a 2024 review by Desarkar et al., the body of research on the therapeutic application of non-invasive brain stimulation is growing and represents advancements in the quality of study, the parameters used in stimulation, and the mechanics of research, and the authors point to the progress of the research. The review also emphasizes limitations and ongoing challenges, including variability in individual response, the need for more standardized dosing protocols, and the importance of precise targeting based on neuroimaging or computational modeling. These findings update earlier assessments that characterized the evidence base as limited or inconsistent, particularly for tDCS, and reflect the increasing rigor of recent randomized and multi-site trials. Combination Therapies Emerging work has explored the joint use of multiple stimulation modalities. A 2024 clinical study by Zhou et al. reported that combined tDCS and repetitive TMS (rTMS) demonstrated promising benefits for insomnia, suggesting potential synergistic effects when protocols are integrated. The given combination is still under research, but it represents a broader tendency toward multimodal stimulation techniques.
The two substrates of this enzyme are (5β)-pregnan-21-ol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (5β)-pregnan-21-al, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 21-hydroxysteroid:NAD+ 21-oxidoreductase. This enzyme is also called 21-hydroxysteroid dehydrogenase (NAD+).
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.